Clinical Trials on Marionette Lines in Australia

Total 15 results

Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Medy-Tox

Completed

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines

Lateral Canthal Lines

Australia
Medy-Tox

Completed

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Glabellar Frown Lines

Australia
BeiGene

Completed

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Australia
Croma-Pharma GmbH

Completed

Princess® RICH for the Correction of Fine Lines (RICH)

Lateral Canthal Lines | Perioral Rhytids

Austria
Ipsen

Completed

Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® (APPEAL)

Glabellar Lines

Australia, Brazil, Czechia, Kazakhstan, Lebanon, Russian Federation, Turkey, Ukraine
Croma-Pharma GmbH
Hugel

Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines (H2H)

Frown Lines

United States, Austria, Canada
Allergan

Completed

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

Glabellar Lines

United States, Canada, Brazil, France, Australia
Merz Pharmaceuticals GmbH

Completed

NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (Head2Head)

Glabellar Frown Lines

United Kingdom, Germany, Austria
AbbVie

Completed

A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Facial Corrections | Facial Lines

Australia, Belgium
St. Jude Children's Research Hospital

Completed

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

Central Line-Associated Bloodstream Infection

United States, Australia
Medical University of Vienna

Completed

Erythema at Exit Site & Tablet Camera

Digital Technology | CLABSI - Central Line Associated Bloodstream Infection | CRBSI - Catheter Related Bloodstream Infection

Austria
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on Marionette Lines in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations